These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 29067491)

  • 1. Impact of malondialdehyde-modified low-density lipoprotein on coronary plaque vulnerability in patients not receiving lipid-lowering therapy: a whole coronary analysis with multislice-computed tomography.
    Ito T; Ichihashi T; Fujita H; Sugiura T; Ohte N
    Heart Vessels; 2018 Apr; 33(4):351-357. PubMed ID: 29067491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of glucose variability on coronary plaque vulnerability in patients with dysglycemia: A whole coronary analysis with multislice computed tomography.
    Ito T; Nakasuka K; Fujita H; Yokoi M; Nakayama T; Sugiura T; Ohte N; Seo Y
    J Cardiol; 2022 Jan; 79(1):58-64. PubMed ID: 34412960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating malondialdehyde-modified low-density lipoprotein levels are associated with the presence of thin-cap fibroatheromas determined by optical coherence tomography in coronary artery disease.
    Matsuo Y; Kubo T; Okumoto Y; Ishibashi K; Komukai K; Tanimoto T; Ino Y; Kitabata H; Hirata K; Imanishi T; Akagi H; Akasaka T
    Eur Heart J Cardiovasc Imaging; 2013 Jan; 14(1):43-50. PubMed ID: 22573905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased Serum Malondialdehyde-Modified Low-Density Lipoprotein and Coronary Angiographic Progression After Drug-Eluting Stent Implantation in Patients With Stable Angina.
    Yokoi M; Ito T; Fujita H; Sugiura T; Seo Y; Ohte N
    Circ J; 2020 Sep; 84(10):1837-1845. PubMed ID: 32863287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Malondialdehyde-modified low-density lipoprotein is a useful marker to identify patients with vulnerable plaque.
    Tajika K; Okamatsu K; Takano M; Inami S; Yamamoto M; Murakami D; Kobayashi N; Ohba T; Hata N; Seino Y; Mizuno K
    Circ J; 2012; 76(9):2211-7. PubMed ID: 22785057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of malondialdehyde-modified low-density lipoprotein on clinical outcomes after fractional flow reserve-guided deferral of revascularization.
    Yokoi M; Ito T; Fujita H; Sugiura T; Seo Y; Ohte N
    Heart Vessels; 2021 May; 36(5):605-614. PubMed ID: 33219835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Malondialdehyde-Modified Low-Density Lipoprotein on Tissue Characteristics in Patients With Stable Coronary Artery Disease　- Integrated Backscatter-Intravascular Ultrasound Study.
    Ikenaga H; Kurisu S; Kono S; Sumimoto Y; Watanabe N; Shimonaga T; Higaki T; Iwasaki T; Mitsuba N; Ishibashi K; Dohi Y; Fukuda Y; Kihara Y
    Circ J; 2016 Sep; 80(10):2173-82. PubMed ID: 27581176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased circulating malondialdehyde-modified low-density lipoprotein levels in patients with ergonovine-induced coronary artery spasm.
    Ito T; Fujita H; Tani T; Sugiura T; Ohte N
    Int J Cardiol; 2015 Apr; 184():475-480. PubMed ID: 25756568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of atorvastatin therapy on fibrous cap thickness in coronary atherosclerotic plaque as assessed by optical coherence tomography: the EASY-FIT study.
    Komukai K; Kubo T; Kitabata H; Matsuo Y; Ozaki Y; Takarada S; Okumoto Y; Shiono Y; Orii M; Shimamura K; Ueno S; Yamano T; Tanimoto T; Ino Y; Yamaguchi T; Kumiko H; Tanaka A; Imanishi T; Akagi H; Akasaka T
    J Am Coll Cardiol; 2014 Dec; 64(21):2207-17. PubMed ID: 25456755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of pravastatin on malondialdehyde-modified low-density lipoprotein levels and coronary plaque regression as determined by three-dimensional intravascular ultrasound.
    Tani S; Watanabe I; Anazawa T; Kawamata H; Tachibana E; Furukawa K; Sato Y; Nagao K; Kanmatsuse K; Kushiro T;
    Am J Cardiol; 2005 Oct; 96(8):1089-94. PubMed ID: 16214443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigation of MDA-LDL (malondialdehyde-modified low-density lipoprotein) as a prognostic marker for coronary artery disease in patients with type 2 diabetes mellitus.
    Kotani K; Tashiro J; Yamazaki K; Nakamura Y; Miyazaki A; Bujo H; Saito Y; Kanno T; Maekawa M
    Clin Chim Acta; 2015 Oct; 450():145-50. PubMed ID: 26265234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk classification of highly sensitive troponin I predict presence of vulnerable plaque assessed by dual source coronary computed tomography angiography.
    Liu T; Wang G; Li P; Dai X
    Int J Cardiovasc Imaging; 2017 Nov; 33(11):1831-1839. PubMed ID: 28528430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum malondialdehyde-modified low-density lipoprotein levels on admission predict prognosis in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
    Amioka N; Miyoshi T; Otsuka H; Yamada D; Takaishi A; Ueeda M; Hirohata S; Ito H
    J Cardiol; 2019 Sep; 74(3):258-266. PubMed ID: 30898480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Malondialdehyde-modified low-density lipoprotein is a predictor of cardiac events in patients with stable angina on lipid-lowering therapy after percutaneous coronary intervention using drug-eluting stent.
    Ito T; Fujita H; Tani T; Ohte N
    Atherosclerosis; 2015 Apr; 239(2):311-7. PubMed ID: 25682029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differences in the CT findings between vulnerable plaque and culprit lesions in acute coronary syndrome.
    Chun EJ; Han JH; Yoo SM; Lee HY; Song IS; White CS
    J Cardiovasc Comput Tomogr; 2018; 12(2):115-117. PubMed ID: 29330042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo evaluation of fibrous cap thickness by optical coherence tomography for positive remodeling and low-attenuation plaques assessed by computed tomography angiography.
    Sato A; Hoshi T; Kakefuda Y; Hiraya D; Watabe H; Kawabe M; Akiyama D; Koike A; Aonuma K
    Int J Cardiol; 2015 Mar; 182():419-25. PubMed ID: 25596470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incremental prognostic value of quantitative plaque assessment in coronary CT angiography during 5 years of follow up.
    Nadjiri J; Hausleiter J; Jähnichen C; Will A; Hendrich E; Martinoff S; Hadamitzky M
    J Cardiovasc Comput Tomogr; 2016; 10(2):97-104. PubMed ID: 26837235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of epicardial fat volume on coronary artery disease in symptomatic patients with a zero calcium score.
    Ito T; Suzuki Y; Ehara M; Matsuo H; Teramoto T; Terashima M; Nasu K; Kinoshita Y; Tsuchikane E; Suzuki T; Kimura G
    Int J Cardiol; 2013 Sep; 167(6):2852-8. PubMed ID: 22882959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of serum homocysteine levels with the severity and calcification of coronary atherosclerotic plaques detected by coronary CT angiography.
    Sun Q; Jia X; Gao J; Mou W; Tong H; Wen X; Tian Y
    Int Angiol; 2014 Aug; 33(4):316-23. PubMed ID: 25056163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of Serum Lipid Profile With Coronary Computed Tomographic Angiography-derived Morphologic and Functional Quantitative Plaque Markers.
    Baumann S; Kryeziu P; Tesche C; Shuler DC; Becher T; Rutsch M; Behnes M; Stach K; Jacobs BE; Renker M; Henzler T; Haubenreisser H; Schoenberg SO; Weiss C; Borggrefe M; Schwemmer C; Schoepf UJ; Akin I; Lossnitzer D
    J Thorac Imaging; 2019 Jan; 34(1):26-32. PubMed ID: 30142137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.